Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Sam Agresta et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret O’Donnell, Ndiya Ogba, Martin S. Tallman et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 655
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCourtney L. Jones, Craig T. Jordan, Brett M. Stevens et al.|Cancer Cell|2018Cited by 565
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Craig T. Jordan, Daniel A. Pollyea et al.|Cancer Discovery|2020Cited by 550